Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toyama Chemical: Net Profits Down Despite Growth in Sales
November 27, 2006
- NEW PRODUCTS
November 27, 2006
- Yakult Aims to Become Oncology-Centered Specialty Pharma
November 27, 2006
- Overseas Business Drives Sales, Profits of 4 Domestic Megas in 1st Half of FY2006
November 27, 2006
- BUSINESS NEWS IN BRIEF
November 27, 2006
- Sawai May Consider Comprehensive Alliance with New Drug Makers
November 27, 2006
- Towa Pharmaceutical: Sales Rise 12.2% to \13,324 Mil.
November 27, 2006
- Nippon Chemiphar: Sales of GE Drugs Up 18% in 1st Half
November 27, 2006
- JMA Members' View of Generics: Follow-up Report
November 27, 2006
- Covance CRU Honolulu Conducts Bridging Studies in Japanese, MD Studies: Dr Ruckle
November 27, 2006
- 46th Annual Scientific Meeting of JSNM
November 27, 2006
- R&D NEWS IN BRIEF
November 27, 2006
- Wyeth Plans to Apply for Prevenar in Japan in 2007
November 27, 2006
- Kowa Pharm. Aims for Sales of \100 Bil. in FY2010: President Tamura
November 27, 2006
- Council to Propose Reference Price System Again
November 27, 2006
- Seminar
November 27, 2006
- Torrent of Questions on FTC Regarding "Joint Purchases" at Ryukaikon
November 27, 2006
- MPC Determined to Expand Business Infrastructure in US, China
November 27, 2006
- REGULATORY NEWS IN BRIEF
November 27, 2006
- Ono to Return to Growth Track in FY2007: Mr Korekane
November 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…